Gastric cancer and the TNT era: have we solved the timing question, or only redistributed the treatment? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Gastric Cancer in the TNT Era: Have We Resolved the Timing Dilemma or Just Altered Treatment Approaches?

  • By

  • Serdar Gumus

  • Ibrahim Cogal

  • Ishak Aydın

  • Cem Kaan Parsak

  • September 15, 2026

Share

  • 1

    Perioperative chemotherapy is standard care for locally advanced resectable gastric cancer, supported by landmark studies.

  • 2

    The independent oncological value of treatment timing in gastric cancer remains uncertain due to methodological limitations in trials.

  • 3

    Western studies focus on the benefits of neoadjuvant therapy, while East Asian studies emphasize the role of adjuvant therapy after high-quality surgery.

  • 4

    Landmark trials primarily assessed the addition of systemic therapy rather than the timing of its administration relative to surgery.

  • 5

    Future research should directly compare perioperative and postoperative systemic regimens to clarify the impact of treatment timing.

Original Source(s)

Gastric cancer and the TNT era: have we solved the timing question, or only redistributed the treatment?

  • by Serdar Gumus, Ibrahim Cogal, Ishak Aydın, Cem Kaan Parsak

  • September 15, 2026

Related Content

Case Report: Treatment of an unresectable mucoepidermoid carcinoma with osimertinib

Correction: Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare WDR43::ALK structural deletion

Retraction Note: Lycorine inhibits angiogenesis by docking to PDGFRα